Technology
Health
Pharmaceutical

Clearside Biomedical

$1.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell CLSD and other stocks, options, ETFs, and crypto commission-free!

About CLSD

Clearside Biomedical, Inc. Common Stock, also called Clearside Biomedical, is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Read More Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Employees
50
Headquarters
Alpharetta, Georgia
Founded
2011
Market Cap
43.77M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
579.05K
High Today
$1.20
Low Today
$1.16
Open Price
$1.19
Volume
247.16K
52 Week High
$10.83
52 Week Low
$0.95

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Therapy
2016 IPO
US

CLSD Earnings

-$0.75
-$0.63
-$0.52
-$0.40
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.